Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Citations Over TimeTop 10% of 2013 papers
Abstract
Bromodomains (BRDs) are epigenetic readers that recognize acetylated-lysine (KAc) on proteins and are implicated in a number of diseases. We describe a virtual screening approach to identify BRD inhibitors. Key elements of this approach are the extensive design and use of substructure queries to compile a set of commercially available compounds featuring novel putative KAc mimetics and docking this set for final compound selection. We describe the validation of this approach by applying it to the first BRD of BRD4. The selection and testing of 143 compounds lead to the discovery of six novel hits, including four unprecedented KAc mimetics. We solved the crystal structure of four hits, determined their binding mode, and improved their potency through synthesis and the purchase of derivatives. This work provides a validated virtual screening approach that is applicable to other BRDs and describes novel KAc mimetics that can be further explored to design more potent inhibitors.
Related Papers
- → Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4(2015)1,016 cited
- → Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain(2018)118 cited
- → Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734(2020)85 cited
- → Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk(2016)48 cited
- → Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors(2019)29 cited